Background/Aims: Breast cancer (BC) is the most common cancer in women worldwide. Despite great advancements in cancer therapy in recent years, surgery and chemotherapy are still the mainstays of BC treatment. However, cancer cells usually develop mechanisms to evade cell death induced by chemotherapy. Thus, strategies are needed to reverse the chemoresistance of cancer cells. Methods: We established cisplatin-resistant BC models in MDA-MB-231 and MCF-7 BC cell lines through long-term exposure to cisplatin. Quantitative reverse transcription PCR was used to examine the expression of microRNA (miR)-100. MTT cell viability assays were performed to determine cell viability. Regulation of hematopoietic western blotting and luciferase reporter assays. The mitochondrial membrane potential and into the cytoplasm, HAX-1 expression, and activation of caspase-9 and caspase-3 were detected by western blotting. Results: A clear decrease in miR-100 expression was observed in cisplatin-resistant MDA-MB-231 and MCF-7 cells (MDA-MB-231/R and MCF-7/R). Overexpression of miR-100 increased the sensitivity of MDA-MB-231/R and MCF-7/R cells to cisplatin treatment and promoted cisplatin-induced mitochondrial apoptosis by targeting HAX-1 gene. Conclusions: MiR-100 targeted HAX-1 to increase the chemosensitivity of BC by mediating the mitochondrial apoptosis pathway.
Introduction
Breast cancer (BC) is the most common cancer in women worldwide. It causes high mortality because of metastatic spread of the cancer cells to vital organs [1, 2] . Currently, surgical resection and chemotherapy are still the main treatment strategies for this disease [3, 4] . However, many patients with BC exhibit a poor response to systematic chemotherapy [5, 6] . Thus, there is an urgent need to develop strategies that reverse the chemoresistance of BC cells.
Cisplatin is an effective broad-spectrum platinum-based anticancer drug used for the treatment of various cancers, including BC. Its mechanism of action involves binding to DNA nucleobases and inducing DNA damage by forming platinum-DNA adducts that trigger apoptosis in cancer cells [7, 8] . However, continuous exposure to cisplatin can cause cancer cells (including BC cells) to develop mechanisms to survive cisplatin treatment [9] [10] [11] . Thus, novel interventions are required to reverse chemoresistance to cisplatin in BC treatment.
MicroRNAs (miRNAs) are a class of endogenously expressed and non-coding small of target miRNAs. Studies have reported that dysregulation of miRNAs is responsible for tumorigenesis and cancer development, because miRNAs participate in various biological processes, including cell proliferation, differentiation, and apoptosis [12] [13] [14] . Moreover, dysregulation of miRNAs induces cisplatin resistance in many cancers including BC [15, 16] . Therefore, targeting dysregulated miRNAs may be a potential strategy for improving the
In this study, we investigated the ability of miRNA (miR)-100, a potential tumor suppressor, to reverse cisplatin resistance in BC.
Materials and Methods

Cell culture
Human breast cancer cell lines MDA-MB-231 and MCF-7 were purchased from American Type Culture 2 incubator. To establish cisplatin-resistant BC models, MDA-MB-231 and MCF-7 cells were exposed to increasing concentrations of Quantitative reverse transcription real time PCR Total RNA was extracted from MDA-MB-231, MDA-MB-231/R, MCF-7, and MCF-7/R cell lines using TRIzol ® reagent (Invitrogen, Carlsbad, CA). For analysis of miR-100 expression, total RNA was reverse transcribed using stem-loop reverse transcription primers and the PrimeScript RT Cell viability assay BC cells were seeded in 96-well plates at a density of 5×10 3 cells per well overnight at 37°C. Subsequently, the cells were treated with different concentrations of cisplatin, carboplatin, and oxaliplatin for 48 h. Cell viability was evaluated using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay as previously described [18] . The absorbance was read at 570 nm using a microplate reader. The half maximal inhibitory concentration (IC 50 ) of cisplatin, carboplatin, and oxaliplatin was calculated according to the cell viability curve of BC cells.
Western blot analysis
Cells were lysed in RIPA lysis buffer (Cell Signaling Technology [CST], Inc., Danvers, MA). Subsequently, 50 µg total proteins were separated by 12.5% sodium dodecyl sulfate polyacrylamide gel electrophoresis caspase-9, and caspase-3; CST) overnight at 4°C. Next, the membranes were incubated with appropriate horseradish peroxidase-conjugated secondary antibodies for 2 h followed by detection with an enhanced to be apoptotic BC cells.
Mitochondrial membrane potential and apoptosis detection
Tumor growth in nude mice
with intraperitoneal cisplatin twice a week (5 mg/kg) until euthanasia (28 days post-injection). The animal care and experimental protocols were approved by the Animal Care Committee of Shandong Provincial
Statistical analysis
Data are represented as the mean ± standard deviation, and were obtained from three independent experiments. For comparive analyses, one-way analysis of variance and the Bonferroni post-hoc test were used to determine differences. Statistical analysis was performed using SPSS 14.0 software (SPSS Inc., P and MCF-7 cells, respectively. Next, we detected changes in miR-100 expression in these BC cell lines, and found that miR-100 expression was decreased in both cisplatin-resistant BC models (Fig. 1B) . These results suggested that the decrease in miR-100 expression was associated with cisplatin resistance in BC.
Results
Decrease of miR-100 in cisplatin-resistant BC cells
Recovery of miR-100 increased the sensitivity of cisplatin-resistant BC cells to cisplatin treatment
Because miR-100 expression was decreased in cisplatin-resistant BC cells, we transfected MDA-MB-231/R and MCF-7/R cells with miR-100 mimics to restore miR-100 levels in both cell lines ( Fig.  2A) . Results of the MTT assay showed that restoration of miRincreased the sensitivity of MDAof miR-100 in cisplatin-induced cytotoxicity against BC cells, we knocked down miR-100 expression in MDA-MB-231 and MCF-7 cells using miR-100 antisense oligonucleotide (anti-miR-100) (Fig. 2C ). Knockdown of miR-100 in MDA-MB-231 and MCF-7 cells clearly decreased cisplatin sensitivity to these BC cells (Fig. 2D) . These results suggested that restoration of miR-100 reversed cisplatin resistance in BC cells.
MiR-100 targeted HAX-1 in BC
To explore the mechanism by which miR-100 reversed cisplatin resistance, we performed a series of analyses to identify the molecular target of miR-100 in BC. Data from TargetScan, compared to their parental MDA-MB-231 and MCF-7 cells (Fig. 3B) . These data together with MDA-MB-231/R, and MCF-7/R cells (Fig. 3C) . The results of the luciferase reporter assay showed that co-transfection with miR-100 decreased the luciferase activities of pMIRbe induced by decreasing miR-100 levels. 
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MiR-100 reversed cisplatin resistance in BC cells by suppressing the HAX-1 pathway
we performed gain-of-function and loss-of-function experiments. As shown in Fig. 4A , of cisplatin against MDA-MB-231/R and MCF-7/R cells, similar to miR-100 (Fig. 4B ). Both MCF-7/R cells. However, miR-100-mediated cisplatin-induced apoptosis could be inhibited sensitivity of cisplatin-resistant BC cells to cisplatin-induced apoptosis. Restoration of miR-100 may represent a potential approach for reversing cisplatin resistance in BC. (Fig. 5A) . Furthermore, co-treatment with miR-100 was promoted release of cytochrome c in cisplatin-treated MDA-MB-231/R and MCF-7/R cells (Fig. 5B) . The results showed that combination treatment with cisplatin and miR-100 expression of caspase-9 and caspase-3, which are apoptotic executors in MDA-MB-231/R and MCF-7/R cells (Fig. 5C ). In addition, the overexpression of pathway in MDA-MB-231/R and MCF-7/R cells co-treated with cisplatin and miR-100. Taken together, these results demonstrated that expression of miR-100 increased the sensitivity of cisplatin-resistant BC cells to cisplatin-induced
Expression of miR-100 improved the anti-tumor effects of cisplatin in cisplatin-resistant BC models in vivo
To investigate the effects of exogenous miR-100 on improving the anti-tumor effects of cisplatin in cisplatin-resistant BC model in vivo, MDA-MB-231/R cells transfected with exhibited obvious resistance to cisplatin treatment. However, mice transfected with miR-100-overexpressed MDA-MB-231/R cells showed more sensitivity to cisplatin treatment MB-231/R cells before treatment with 5 mg/kg cisplatin twice a week. Tumor volumes were detected every 3 days until euthanasia (28 days post-injection). B: Quantitative reverse transcription PCR assays were performed to detect the expression of miR-100 in tumor tissues resected from tumor-bearing mice (*P<0.05 miR-100-transfected MDA-MB-231/R cells was obviously inhibited (Fig. 6C) . These results demonstrated that expression of miR-100 improved the anti-tumor effects of cisplatin in in vivo.
Expression of miR-100 reversed the resistance of MDA-MB-231/R and MCF-7/R cells to platinum-based chemotherapy drugs
The results of the MTT assay showed that cisplatin-resistant MDA-MB-231 and MCFHowever, miR-100 expression in these cisplatin-resistant BC cells reversed the resistance to platinum-based chemotherapy drugs and decreased the IC 50 of carboplatin (Fig. 7C) and oxaliplatin (Fig. 7D) to MDA-MB-231/R and MCF-7/R cells. These results indicated that expression of miR-100 was able to reverse the resistance of BC cells to platinum-based chemotherapy.
Discussion
Recent studies have indicated that changing miRNA expression is an important mechanism by which cancer cells develop chemoresistance to various anti-cancer drugs. Among the dysregulated miRNAs, miR-100 downregulation has been found in multiple cancers. Because miR-100 reportedly inhibits cancer development and promotes cancer cells apoptosis, it is considered to be a potential tumor suppressor [23] [24] [25] [26] . In addition, some studies have reported that the absence of miR-100 is associated with a poor prognosis therapeutic strategy for cancer.
In this study, we focused on the potential role of miR-100 in cisplatin resistance in BC. miR-223 expression between cisplatin-resistant BC cells and their parental cells. Meanwhile, the reduction of miR-125a (reduced by 13.5%) and miR-125b (reduced by 16.9%) expression was slight when BC cells became cisplatin-resistant (Fig. 8) . Mechanistically, our resistant BC cells. Restoration of miR-100 was able to suppress the aberrant expression of Development of cisplatin resistance in cancer cells usually induces resistance to platinum derivatives [40] . In our study, we also observed the resistance of cisplatin-resistant BC cells to carboplatin and oxaliplatin. However, combination treatment with miR-100 reversed the resistance to these platinum-based anti-tumor drugs.
Taken together, the results of this study provide strong evidence that the miR-100/ Combination treatment with miR-100 may represent an effective approach for improving the anti-tumor effects of platinum-based chemotherapeutic drugs in BC. 
